Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

There are currently no approved drugs for the treatment of emerging viral infections, such as dengue and Ebola. Adaptor-associated kinase 1 (AAK1) is a cellular serine-threonine protein kinase that functions as a key regulator of the clathrin-associated host adaptor proteins and regulates the intracellular trafficking of multiple unrelated RNA viruses. Moreover, AAK1 is overexpressed specifically in dengue virus-infected but not bystander cells. Because AAK1 is a promising antiviral drug target, we have embarked on an optimization campaign of a previously identified 7-azaindole analogue, yielding novel pyrrolo[2,3- b]pyridines with high AAK1 affinity. The optimized compounds demonstrate improved activity against dengue virus both in vitro and in human primary dendritic cells and the unrelated Ebola virus. These findings demonstrate that targeting cellular AAK1 may represent a promising broad-spectrum antiviral strategy.

Original publication

DOI

10.1021/acs.jmedchem.9b00136

Type

Journal article

Journal

Journal of medicinal chemistry

Publication Date

12/06/2019

Volume

62

Pages

5810 - 5831

Addresses

Medicinal Chemistry, Rega Institute for Medical Research , KU Leuven , Herestraat 49-bus 1041 , 3000 Leuven , Belgium.

Keywords

Cell Line, Humans, Pyridines, Protein-Serine-Threonine Kinases, Protein Kinase Inhibitors, Antiviral Agents, Protein Conformation, Structure-Activity Relationship, Chemistry Techniques, Synthetic, Molecular Docking Simulation